Kappa opioid receptor antagonists are provided that yieldsignificant improvements in functional binding assays to kappaopioid receptors relative to nor-BNI, and the use of theseantagonists in treatment of disease states that are ameliorated bybinding of the kappa opioid receptor such as heroin or cocaineaddictions.
Kappa opioid receptor ligands
Carroll, F., Thomas, J., & Mascarella, S. (2005). IPC No. U.S. Kappa opioid receptor ligands. (U.S. Patent No. 6974824).